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CHAPTER I: 
INTRODUCTION 
Chromium is a trace metal required for normal carbohydrate and lipid metabolism 
and glucose homeostasis (55, 72). By increasing the activity of insulin while requiring less 
insulin for heightened activity (37), chromium has been shown to potentiate the action of 
insulin (14, 59, 71). Although no recommended daily allowance has been established, the 
National Research Council recommends an estimated safe and adequate daily dietary intake 
of trivalent chromium of between 50 to 200 µg (58). However, approximately 90 percent of 
the U.S. population may be consuming less than the recommended minimum daily intake of 
50 µg (6, 9, 41 ). Furthermore, a large segment of the U.S. population may be at risk of at 
least a marginal deficiency in trivalent chromium (56, 64) due to the high consumption of 
refmed, processed, and preserved foods that have lower chromium content than their raw 
food sources (64). Dietary chromium can be obtained through consumption of organ meats, 
cheese, wheat germ, Brewer's yeast, wine, and beer (29, 58). 
Signs of marginal chromium deficiency include impaired glucose tolerance, elevated 
concentrations of fasting insulin, elevated circulating insulin, decreased insulin binding, 
decreased insulin receptor number, glucosuria, elevated cholesterol and triglycerides, 
decreased HDL cholesterol, and hypoglycemic symptoms (3, 9, 14, 71). Additionally, 
specific stresses shown to enhance chromium losses are pregnancy and lactation (10, 27), 
high sugar diets (4, 41), physical trauma (14), and strenuous exercise (3, 41). The latter is 
noted as a characteristic of athletes and other highly active individuals. Although dietary 
sources of chromium can be found in foods, (58), the risk of deficiency in certain populations 
may suggest a need for chromium supplementation. Furthermore, an established therapeutic: 
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toxic dose ratio of 1: 10,000 µg (58) makes trivalent chromium among the safest nutritional 
elements. Signs of toxicity have not been observed even after prolonged application ofGTF 
supplementation (35). In early studies chromium is referred to as Glucose Tolerance Factor. 
Trivalent chromium is the. most bioavailable form of chromium. Furthermore, 
chromium III absorption may be increased several fold when combined with picolinic acid. 
Thus, chromium picolinate is a compound of one trivalent chromium atom surrounded by 
three molecules ofpicolinic acid (16). Trivalent chromium and chromiumpicolinate 
supplementation have been shown to improve glucose and lipid metabolism and protein 
anabolism (2, 4, 8, 9, 34, 37, 39, 40, 44, 55,69) in animals, healthy persons, and non-healthy 
people. Consequently, both trivalent chromium and chromium picolinate have been 
promoted as a dietary supplement claiming to enhance weight loss and athletic performance 
by decreasing body fat and enhancing gains in lean body mass (24, 40). However, previous 
studies investigating the relationship between exercise and chromium picolinate intake have 
demonstrated conflicting results (18, 24, 31, 33). 
Chromium picolinate supplementation (200 µg/day) with weight training was shown 
to enhance gains in lean body mass with decreases in body fat beyond that achieved with 
training alone in collegiate football players (24). Conversely, other research suggests that 
chromium picolinate supplementation (200 µg/day) does not facilitate changes in body 
composition or strength during a program of intense weight lifting in male football players 
(18). However, when taken during a moderate strength training program, chromium 
picolinate supplementation (200 µg/day) was shown to increase body weight in female 
subjects with no change in lean body mass or body fat percentage (33). Thus, because lean 
tissue is known to weigh more that fatty tissue and no increases in body fat were observed, 
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these fmdings indicate an increase in lean body mass beyond that achieved from training 
alone when subjects were supplemented with 200 µg of chromium picolinate daily (33). 
More recently, Hallmark et al. (31) concluded that chromium supplementation when taken in 
combination with a progressive resistive training program, did not promote a significant 
increase in strength and lean body mass nor a significant decrease in percent body fat (31 ). 
These conflicting fmdings may be due to the variances in control of diet, 
cardiovascular activity, and resistance training protocols. Although numerous studies have 
demonstrated a relationship between glucose homeostasis and lipid metabolism and trivalent 
chromium or chromium picolinate supplementation (2, 4, 8, 9, 34, 37, 39, 40, 44, 55,69), few 
studies have actually demonstrated the relationship between the metabolic function of 
chromium picolinate and improved fat loss and gains in lean body mass. Furthermore, no 
published studies have investigated the effects of chromium picolinate supplementation in 
healthy female subjects participating in a moderate exercise program including both 
cardiovascular and resistance training. Nevertheless, nutritional supplements such as 
chromium picolinate, "Chroma Slim", "Fat Burners", "Cyber Slim", and other weight loss 
enhancing and body building products that contain chromium picolinate are widely promoted 
to meet America's fast paced lifestyle as a quick fix remedy to obesity. Additionally, many 
product labels encourage consurners to engage in a regular exercise program when taking 
their respective supplement despite the lack of confirmed findings. Consequently, the 
purpose of this study was to investigate the effects of chromium picolinate supplementation 
(200 µg/day) on changes in body composition, muscular strength, muscle girth, and body 
weight in young women with a moderate exercise program including both cardiovascular and 
resistance exercise. Based on previous research indicating that females may respond more 
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readily to chromium picolinate supplementation, it is the hypothesis of this study that young 
healthy females supplemented with 200 µg of chromium picolinate while participating in a 
combined resistance and cardiovascular exercise program will experience a decrease in body 
fat and increase in lean body mass beyond that achieved with training alone. 
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CHAPTER II: 
LITERATURE REVIEW 
Physiological role of chromium 
Chromium has been identified as the active component of Glucose Tolerance Factor 
(GTF), a dietary ingredient required for optimal glucose metabolism (55, 72). Trivalent 
chromium is believed to act as a co-hormone of insulin by potentiating and amplifying its 
action (35, 38, 59, 71). Although its specific action on these cells is unknown (10), trivalent 
chromium has been suggested to form complexes with insulin and the mitochondria 
involving chromium and sulfur linkages at the mitochondrial membrane of tissues (15, 17). 
Chromium deficiency is associated with glucose intolerance and elevated mean blood 
chromium levels after a glucose load in humans ( 45). Chromium deficiency has also been 
acknowledged as a contributor to hyperglycemia ( 45). Rats deficient in chromium have been 
found to display disturbed glucose metabolism simulating that of Non Insulin Dependent 
Diabetes Mellitus (NIDDM) (63). Low chromium intake has also been shown to lead to 
d~trimental effects on glucose tolerance, insulin, and glucagon in humans with mildly 
impaired glucose tolerance (9). The most extensively studied chromium deficient tissue in 
vitro has been the rat epididymal fat pad in which chromium increased the rate of glucose 
uptake, oxidation of glucose, and incorporation of glucose carbon into fat in the presence of 
insulin ( 49). Similar increases in glucose uptake have been observed with dietary chromium 
supplementation in rats (49, 55). Additionally, chromium supplementation may restore 
impaired functions to near normal within two hours of supplementation ( 49). 
Additionally, GTF prepared from Brewer's yeast produced a 36% reduction in plasma 
glucose in mice without disturbing liver glucose production (55, 68). Glucose tolerance, 
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insulin, and glucagon secretion have also all been shown to improve during chromium 
supplementation in humans (9). However, higher or lower doses than those used (200 
µg/day) were less effective (68). Thus, it appears that repletion of chromium improves 
hyperglycemia to a certain degree but more than normal amounts of insulin are still required 
to regulate the elevated glucose (45). However, each of these studies supplemented subjects 
with the same dose amount of chromium regardless of differences in sex, body weight, or 
lean body mass. Although blood chromium increased with a glucose load ( 45) reinforcing 
the relationship between glucose homeostasis and chromium status, perhaps the relationship 
between chromium dose to sex and lean body mass should be considered. 
Chromium supplementation has also been suggested to have beneficial effects on 
lipid metabolism, cholesterol levels, and certain lipoproteins (1, 20). Rabbits fed a 
thermogenic diet with daily chromium injections were observed to have reduced total 
cholesterol content of the aorta and reduced areas of the aortic intima covered by plaques (1). 
Furthermore, chromium may influence cholesterol synthesis in rats by allowing phospholipid 
oxidation and increasing cholesterol synthesis (1 ). Thus, it has been suggested that 
chromium deficiency may be associated with a variety of parameters involved in the risk of 
atherosclerosis, including diabetes (1 ). It has also been suggested that chromium 
supplementation may prove to have health benefits beyond those associated with a healthy 
percentage of body fat and a healthy weight. 
In addition to the role of chromium in glucose and lipid metabolism, chromium 
deficiency has been associated with alterations in nitrogen anabolism. Chromium deficiency 
has been shown to cause weight loss unless energy intake was increased by 55% due to its 
effects on protein anabolism and growth (39). Rats deficient in chromium were also shown 
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to have diminished growth rates, which returned to normal with chromium supplementation 
(52) indicating the role of chromium in muscle growth. Furthermore, rats with sufficient 
chromium stores had improved growth and survival (63) while both male and female 
supplemented rats have been shown to weigh more than chromium deficient rats (63). 
Chromium has also been shown to be retained by bone and has been associated with skeletal 
growth ( 63). Immature bone has been shown to retain 12% of a chromium dose 24 hours 
after injection while mature bo.ne retained only 5% (63). Despite improved glycogen and 
protein synthesis in response to insulin with chromium intake, it is important to note that the 
improved effectiveness of insulin and increased growth in chromium supplemented rats 
cannot be attributed to chromium alone because of the many other hormones and factors 
involved in growth (64). Furthermore, while chromium deficiency appears to slow growth, it 
has been noted that the effect of chromium deficiency on impaired growth is not perceived as 
impressive when compared with the cessation of growth observed in deficiencies of other 
trace elements (63). 
Chromium appears to be effective in very small amounts as only two to three percent 
of an oral chromium dose is absorbed in a rat model (49). Of the few percent of dietary 
chromium absorbed in the rat, more than half is excreted within the following day. 
Furthermore, while chromium infusion was shown to improve protein anabolism, lipid 
related abnormalities, and decrease glucose levels to normal with three days of application 
(39), excess chromium was excreted in the urine. Consequently, chromium stores appear to 
become saturated (39) and intake beyond saturation is not used. Thus, individuals with 
sufficient chromium stores possibly would not benefit from supplementation. Furthermore, 
ingesting supplements beyond the recommended safe and adequate amounts as suggested by 
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several products may not be beneficial. Products commonly recommend daily 
supplementation of200 µg for women and 400 µg for men. 
Mechanisms of chromium action 
Trivalent chromium is believed to act as a co-hormone of insulin by potentiating and 
amplifying its action (35, 38, 59, 71). Although the mode of interaction between insulin and 
chromium is not known, it has been demonstrated that insulin must be present for chromium 
action and chromium must be present for insulin action ( 49). Chromium appears to act 
directly on the !3-cells of the pancreas (10). Although its specific action on these cells is 
unknown ( 10), trivalent chromium has been suggested to form complexes with insulin and 
the mitochondria involving chromium and sulfur linkages at the mitochondrial membrane of 
tissues (15, 17), thereby enhancing the functional action of insulin at the tissue as compared 
to increasing the production of insulin. Furthermore, trivalent chromium has been suggested 
to bind specifically to siderophilin (transferrin), plasma proteins in the blood, where it 
competes with iron for a binding site (36, 50). The presence oftransferrin and albumin, 
plasma proteins, are thought to be needed in at least subphysiologic levels for maximal 
absorption of trivalent chromium (22). Furthermore, absorption of supplemental chromium 
through the gastrointestinal wall does not appear to be a prerequisite of binding the element 
to the beta globulin :fraction of the blood (36). 
Factors affecting chromium transport and absorption 
Although previous diet has been shown to have no effect on chromium absorption 
(44, 47), nicotinic acid and iron status do appear to affect the responsiveness of individuals to 
chromium supplementation. Iron has been suggested to depress chromium binding and 
people with hemochromatosis retain less chromium than people with normal iron stores (63). 
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Furthermore, less chromium was found to bind to siderophilin (transferrin) as more iron was 
added to the blood stream (63). Picolinic acid and Vitamin B6 have also been suggested to 
affect iron metabolism in cells by overcoming the competition between dietary iron, zinc, 
and possibly chromium (23, 25). Picolinic acid is formed in the body from tryptophan 
metabolites via the action of three separate enzymes (25). Tryptophan is one of the ten 
essential amino acids. At physiological pH, picolinic acid fully dissociates and forms stable 
complexes with essential metals such as chromium and zinc and improves the transport of 
essential metals by overcoming the competition between them and iron (25). Thus, because 
picolinic acid has also been found to affect iron metabolism in cells by withholding iron from 
cells (25), adding picolinic acid may allow selective withholding of iron from the transferrin 
binding site so chromium can bind in its place to induce growth by increasing energy use and 
facilitating protein anabolism (25, 26). This competitiveness may also explain why excess 
iron stores depress chromium binding and inhibit retention in that, perhaps, these proteins 
prefer iron to chromium. Consequently, it may be that adding picolinic acid to chromium 
alters the affinity oftransferrin for iron to prefer chromium for growth enhancement (25, 26). 
Furthermore, Lukaski et al. found that transferrin saturation was decreased 24% more with 
chromium picolinate supplementation than with chromium chloride or placebo ( 46). It is 
interesting to note that many supplements used in body building encourage a high protein 
intake when high protein consumption alone or combined with elevated liver picolinic 
carboxylase in the diabetic rat has been suggested to influence zinc, copper, and other trace 
metal metabolism (40). Nevertheless, the improved insulin sensitivity with chromium intake 
and improved bioavailability of chromium from the addition ofpicolinic acid has resulted in 
the formation of chromium picolinate. 
Chromium picolinate is a compound of one chromium atom surrounded by three 
molecules ofpicolinic acid (33). This compound is suspected to improve the efficiency of 
body fat utilization and the ability to develop and maintain muscle mass (24). Thus, it has 
been suggested that chromium picolinate decreases body weight and body fat while 
enhancing gains in lean tissue when combined with moderate exercise. 
Chromium picolinate and exercise 
The essentiality of chromium to normal metabolism has instigated interest in the 
metabolic effects involved in response to various types of exercise. Endurance exercise 
training has been shown to enhance chromium losses and increase muscle tissue chromium 
levels in rats (70). After progressively increasing running time and intensity up to a 
moderate exercise program, rats ran 60 minutes, six times per week for 12 weeks. 
Additionally, a single bout of running increased chromium excretion in humans (7, 13). 
Furthermore, Evans investigated the relationship of chromium picolinate and body 
composition in two separate studies. Ten male students participated in a university weight 
training class while maintaining their normal dietary and activity habits. Although training 
intensity was not specified, subjects trained twice per week for forty minutes each session 
performing both upper and lower body exercises (24). At the end of the 40 day training 
regime, Evans reported that male subjects consuming chromium picolinate increased body 
weight by 2.2 kg, 73% of which was reported to be due to increased lean body mass alone 
(24) compared to the placebo group whose body weight and percent body fat both increased 
significantly. When the gains and losses of lean body mass and body fat, respectively, were 
compared between groups, the increase in lean body mass of the chromium picolinate 
supplemented men was greater than the placebo group. Consequently, it was concluded that 
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chromium picolinate supplementation (200 µg/day) with weight training enhanced gains in 
lean body mass with decreased body fat beyond that achieved with training alone in male 
weight training students (24). Additionally, collegiate football players volunteered to 
participate in a weight training program four days per week, 60 minutes per session for 6 
weeks (24). However, neither training intensity nor the exercises performed were specified. 
Evans reported that after 14 days, subjects consuming 200 µg of chromium picolinate lost 
2.7% body fat and gained 1.8 kg oflean tissue (24). Furthermore, by the end of the six week 
training regime, subjects taking the supplements had lost 1.2 kg of body weight, gained 2.6 
kg oflean body mass, and lost 3.6% body fat, which is a 23% decrease (24). Additionally, 
when the gains in lean body mass and loss of body fat were compared statistically between 
groups, the lean body mass of the chromium picolinate supplemented group was 44% greater 
than the placebo group, while the decrease in body fat was 3.5 times greater in the chromium 
supplemented men (24). 
More recent fmdings have supported the finding that chromium excretion increases 
with exercise and chromium supplementation, but none have found significant changes in 
lean body mass, fat body mass, or strength in conjunction with a variety of exercise programs 
(18, 33, 43). An investigation by Clancy et al. suggests that chromium picolinate 
supplementation (200 µg/day) does not facilitate changes in body composition nor strength 
during a program of intense weight lifting in male football players (18). Subjects 
participated in spring training for nine weeks while ingesting either 200 µg of chromium 
picolinate or a placebo (18). However, the intensity of weight training was not specified 
(18). 
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In contrast, chromium picolinate supplementation (200 µg/day) of beginning weight 
training students who participated in a moderate strength training program resulted in 
increased body weight in only female subjects with no change in lean body mass or body fat 
percentage of chromium supplemented female subjects (33). Subjects exercised three days 
per week for 40 minutes over 12 weeks performing the bench press, squat, military press, 
bent over row, dumbbell flies, lat pull downs, arm curls, and tricep extensions (33). Subjects 
were instructed to choose a weight that would allow them to complete at least 6 repetitions 
and fatigue them by 10 repetitions (33). The amount of weight lifted was progressively 
increased as strength increased throughout the 12-week training program. The chromium 
picolinate supplemented female subjects gained significantly more weight, 2.5 kg as 
compared to 0.6-1.3 kg in the other three groups. The increased body weight within groups 
was also significant in that the group of females supplemented with chromium picolinate 
experienced a 4.3% increase in body weight as compared to a 0.9-2.0% increase in the other 
three groups. The males supplemented with chromium picolinate did not have a greater gain 
in muscle girth than those taking a placebo (33). However, chromium picolinate-
supplemented females showed a 3.0 cm overall increase in muscle girth while females taking 
a placebo showed no measurable increases in muscle girth (33). Nonetheless, the mean 
increase in the sum of circumferences for all groups was 2.3 cm due to training alone (p = 
0.0001). One may postulate that females taking chromium picolinate did experience a 
greater increase in lean body mass beyond that achieved with exercise alone as supported by 
the differences in body weight gains. However, the change in the sum of circumferences or 
skinfolds was not different between groups. These researchers concluded that chromium 
picolinate does not increase body fat loss beyond those due to exercise alone (33). 
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Hallmark, et al. also recently concluded that chromium supplementation in 
conjunction with a progressive resistive exercise training program does not promote a 
significant increase in strength and lean body mass nor a significant decrease in percent body 
fat (31). Subjects trained three times per week for 12 weeks. Two sets of8-10 repetitions 
were performed at 90% of the lRM with 60 seconds rest between sets (31 ). Once 10 
repetitions could be performed, the weight was increased in five pound increments. All 
exercises were performed on Keiser variable resistance exercise machines and included the 
following nine exercises: leg press, leg extension, leg curl, chest press, lat pulldown, 
overhead press, seated row, tricep dumbbell extensions, and bicep curls (31). Although the 
resistance training protocol was highly controlled, no cardiovascular exercise was included. 
Lukaski, et al. examined the effects of3.3-3.5 µmol of chromium chloride or 
chromium picolinate or placebo (0.1 µmol chromium) and resistance training on body 
composition strength and trace element status of men ( 46). Subjects exercised 5 days per 
week for 8 weeks. Subjects initiated workouts with 8-12 repetitions at 50-65% of lRM 
followed by four to 8 repetitions at 70-80% lRM, and concluded with one repetition at 95-
100% lRM. Four exercises were performed including bench press, leg press, leg curls, and 
lateral pull downs. It was concluded that chromium supplementation has no effect on body 
composition or strength in male subjects. ( 46) 
Summary and purpose of investigation 
Healthy people with sufficient chromium storage show elevated plasma chromium 
levels after ingestion of glucose or injection of insulin ( 44). Furthermore, increased blood 
chromium levels in response to an oral glucose tolerance test have been accepted as an index 
of assessing chromium nutritional state when a person has sufficient chromium stores (32). 
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Dietary chromium intake can also be analyzed to identify chromium intake relative to 
chromium excretion. Additionally, when sufficient chromium stores exist, an oral glucose 
tolerance test (OGTT) increases urinary chromium excretion (32). Insulin mobilizes 
chromium so that losses are excreted in the urine (32). Thus, urinary chromium values are 
good indicators ofrecent chromium intake (10, 43, and 48). Although the effects of 
chromium on glucose, lipid, and nitrogen metabolism, insulin action, and chromium 
excretion have been demonstrated, the degree to which these metabolic actions affect 
anthropometric changes with an exercise program remains unclear. Specifically, no studies 
have investigated the claims made to a large segment of the target population, young females. 
Consequently, the purpose of this investigation was to evaluate the effects of chromium 
picolinate supplementation combined with a moderate exercise program, including both 
cardiovascular exercise and resistance training, on changes in body weight, body 
composition, muscle girth and muscle strength in healthy female subjects aged 18 to 24 years 
of age. 
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CHAPTER III: 
METHODS 
Subjects 
Subjects were recruited through campus fliers and class announcements in the 
Department of Health and Human Performance. Twelve subjects were randomly selected 
from a group of female volunteers in the general population. Subjects were randomly 
assigned to placebo (PL; n=6) or a chromium supplemented (CR; n=6) group. Criteria for 
participation included no competitive status, females 18 to 24 years of age, persons who self-
reported to not be taldng or not have taken enhancing supplements in the previous three 
months, absence of anemia as determined by pretraining hematocrit and hemoglobin 
measurements, the absence of diabetes or CVD as determined by an oral glucose tolerance 
test and graded exercise test prior to training, respectively. Both groups participated in an 
eight week supervised cardiovascular and resistance training program. Subjects assigned to 
PL and Cr did not differ with respect to age, height or Body Mass Index (Table 1). 
Table 1: Subject Characteristics 
Group PL CR 
Age (yrs) 21.2 ±2.2 21.5 ± 1.9 
Ht (cm) 168 ± 14.9 169 ± 5.2 
BMI 23.3 ± 1.7 23.6 ± 5.8 
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Supplementation 
CR ingested 200 µg of chromium picolinate daily in capsule form. The placebo 
group ingested an identical capsule containing 200 µg of sucrose as a placebo. Each 
individual was provided with a vial containing the exact number of either chromium capsules 
or placebo capsules at the onset of the exercise program. Each subject was encouraged to 
bring their vial with them to each exercise session so that the remaining capsules could be 
counted and ingestion monitored. Each subject was also reminded at each exercise session to 
take their capsules. 
Training regimen 
Cardiovascular and resistance training exercises were designed to increase the fitness 
level of women subjects women aged 18-24 years of age. Both PL and CR participated in 
resistance and cardiovascular activity for 8-weeks. An 8-week training regimen was selected 
based on recommendations that training adaptations occur within four to 20 weeks when 
subjects exercise 2-3x per week(28). Subjects performed a progressive resistance training 
and cardiovascular exercise program according to the schedule outlined in Table II. 
Table II: Training Regimen 
Resistance Training 
Week Frequency Intensity 
I, II MWF 65% lRM 
III-VI MWF 85% lRM 
VII, VIII MF 95% lRM 
Cardiovascular Training 
Sets/Repetitions Time Frequency 
3 x 12 repetitions 30 min. T, Th 
3 x 8-10 repetitions 30 min. T, Th 
5 x 3-5 repetitions 30 min. T, Th 
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Each subject performed three sets of repetitions on three lower body, Keiser (Fresno, 
CA) variable resistance training machines. Exercises were selected to train the large muscle 
groups of the lower body. Subjects performed the leg press, leg curl, and knee extension 
exercises three times per week throughout the first 6 weeks followed by just two sessions per 
week the final two weeks. The amount of weight lifted was initiated at 65% of the initial 
lRM for the first two weeks. During the subsequent four weeks, subjects lifted a resistance 
equal to 85% of the initial IRM. Subjects lifted at 95% of their initial IRM throughout the 
fmal two weeks. Thus, the number of repetitions decreased according to the amount of 
weight lifted from three sets of 10-12 repetitions to three sets of 8-10 repetitions to five sets 
of3-5 repetitions or to failure. One repetition maximums were determined after two practice 
trials performed on two separate days, a minimum of two days prior to the actual testing. 
The I -RM during practice trials was used to determine the starting weight during testing. All 
subjects performed a light, rhythmic cardiovascular warm up and stretching 5 minutes prior 
to testing. Subjects attempted one maximal exertion followed by 2-3 minutes of rest before 
attempting another maximal exertion at a resistance approximately 5% greater than the 
previous attempt. The I-RM was obtained in 4 or fewer attempts for each subject. All 
testing and training was performed on Keiser variable resistance equipment including the 
Leg Press, Leg Curl, and Knee Extension. Training records were filed at the end of each 
workout and collected at the end of each week throughout the 8-week training program. The 
researchers and research assistants monitored all exercise sessions. Additionally, both 
groups participated in 30 minutes of cardiovascular exercise on a treadmill, Stairmaster, or 
cycle ergometer on the two days per week when they were not lifting weights. Subjects 
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exercised at 65% of their HR.peak the first two weeks, and 70% of their HR.peak throughout the 
final 6 weeks of the study. Peak heart rates achieved were measured using a Polar heart rate 
monitor during a maximal graded exercise test performed on each subject. 
Intensity levels for both resistance training and cardiovascular exercise were selected 
based on recommendations of the American College of Sports Medicine (28). The American 
College of Sports Medicine suggests that exercise intensities of at least 60% of a lRM should 
be sufficient to increase strength. Additionally, the most rapid strength gains are achieved 
when a muscle is exercised at 80-100% of maximum exertion. To continue improving 
muscle strength with resistance training, the workload must be progressively increased to 
continue overloading the muscle. Furthermore, ACSM recommends exercising at 70-85% of 
the heart rate achieved on symptom-limited treadmill test, for 20-60 minutes, 3-5 days per 
week. A lower cardiovascular intensity was chosen during the first two weeks of training so 
that all subjects could complete the 30 minutes in the early phase of conditioning. 
Additionally, 70% of peak heart was selected for the remaining six weeks to minimize the 
risk of injury and improve subject compliance. Heart rates were taken manually by the 
researchers and/or research assistants. 
Analyses 
Measurements were taken before and after the eight week training period. Three-day 
food intake records were recorded by each subject during the pre testing measurements so 
that subjects could duplicate their food intake during the days preceding the post testing to 
insure that the same food was eaten prior to each glucose tolerance test. Maximal oxygen 
uptake was measured using commercial software (TurboFit, Vacumed, Ventura, CA) and the 
Bruce Protocol Treadmill test to determine appropriate exercise intensities throughout the 
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training regime and to measure changes in cardiovascular capacity. Oxygen consumption, 
expired gases, heart rate, and RPE were collected throughout each test. All testing was 
performed in the Exercise Clinic at Iowa State University. One repetition maximum exertion 
was measured after three practice trials during the week prior to the initial training session 
and the week following the last training session. Testing was performed on the leg press, 
knee extension, and leg curl machines to determine training intensity and measure changes in 
muscular strength. One repetition maximum testing was also performed after each training 
intensity. Body composition using skinfold calipers at 9 sites, body weight, and muscle 
girths at 8 sites were measured before training, after each training intensity, and post training. 
Hydrostatic weights were measured pre and post testing. Body compositions were calculated 
using Jackson-Pollock equations (28). Hemoglobin and hematocrit were measured during 
pre-testing to insure the absence of anemia in subjects throughout the study. 
Statistical analyses 
A Two Way Repeated Measures Analysis of Variance (ANOVA) was performed to 
examine changes in all training and anthropometric variables. Data are reported as means 
±SEM. A level of significance was set a P<0.05 for all statistical analyses. Neuman-Keuls 
multiple comparison tests were performed to determine the effect of each training intensity 
on individual variables. Two subjects did not participate in the final training stages nor post 
testing due to one having kidney stones and the other developing mononucleosis. Missing 
data were calculated using the formula and method ofOstle and Mensing (59). 
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CHAPTER IV: 
RESULTS 
Muscle strength 
Leg press strength was not different between the placebo supplemented group (PL) 
and the group supplemented with 200 µg of Chromium Picolinate (CR) before or after 
training. Additionally, supplementation did not increase strength beyond that achieved from 
training alone. When data from PL and CR are combined, training increased leg press 
strength from 3,348 N ± 113 to 3,789 N ± 113 pre and post training (Figure 1; p < 0.001). 
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PRE POST 
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Leg Press 1-RM before and after a progressive, lower body, 8-week resistance 
training program combined with 200 µg/day chromium picolinate (CR, n=6) 
and placebo (PL, n=6) supplementation. Data are means ± SE. Leg Press 
1 RM was significantly greater after training in both CR and PL ( significant 
main effect; p < 0.001). · 
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Knee extension strength was not different in the PL and CR before or after training. 
When data from PL and CR are combined, training increased knee extension strength from 
515 N ± 20 to 621 N ±2 0), (Figure 2; p < 0.001). 
Leg curl strength was not different in the PL and CR before or after training. When 
data from PL and CR are combined, leg curl strength increased from 528 N ± 22 to 632 ± 22, 
(Figure 3; p<0.001) 
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Knee Extension I-RM before and after a progressive, lower body, 8-week 
resistance training program combined with 200 µg/day chromium picolinate 
(CR, n=6) and placebo (PL, n=6) supplementation. Data are means ± SE. 
Knee Extension IRM was significantly greater after training in both CR and 
PL (significant main effect; p < 0.001). 
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PRE vs. POST, main effect (p < 0.001) 
PRE POST 
PL 
PRE POST 
CR 
Leg curl 1-RM before and after a progressive, lower body, 8-week 
resistance training program combined with 200 µg/day chromium 
picolinate (CR, n=6) and placebo (PL, n=6) supplementation. D_ata are 
means ± SE. Leg Curl lRM was significantly greater after training in 
both CR and PL (significant main effect; p < 0.001). 
Cardiovascular adaptations to training 
Peak oxygen consumption (V02peak) was not different between PL and CR before or 
after training. Although supplementation did not enhance improvements in cardiovascular 
capacity, when data from PL and CR are combined, peak oxygen consumption increased 
from 41.0 ml/kg/min± 2.1 to 48. 7 ml/kg/min± 2.1 due to training (Figure 3). Furthermore, 
oxygen consumption during stages I and II of the Bruce Protocol increased nearly twice as 
much in CR compared with PL after training. Oxygen consumption increased 5.5% more in 
CR during stage III and 6.3% in Stage IV than PL. 
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PRE vs. POST, main effect, (p < 0.02) 
PRE POST PRE POST 
PL CR 
Figure 4. Peak oxygen consumption during a graded maximal treadmill test before and 
after an 8-week moderate cardiovascular program combined with 200 µg/day 
chromium picolinate (CR, n=6) and placebo (PL, n=6) supplementation. Data 
are means ± SE. Peak Oxygen consumption was significantly greater after 
training in both CR and PL (significant main effect; p < 0.02). 
Peak heart rate achieved during a graded, symptom limited treadmill test was not 
different between PL and CR before training or after performing 8-weeks of cardiovascular 
exercise. When data from PL and CR are combined, peak heart rate achieved increased from 
189 bpm ± 4 to 193 bpm ± 4, (Figure 5; p = 0.003) with training. 
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PRE vs. POST, main effect, (p < 0.003) 
PRE POST PRE POST 
PL CR 
Peak heart rate during a graded maximal treadmill test before and after 
an 8-week, moderate cardiovascular program combined with 200 
µg/day chromium picolinate (CR, n=6) and placebo (PL, n=6) 
supplementation. Data are means ± SE. Peak heart rate achieved was 
significantly greater after training (significant main effect; p < 0.003). 
Body mass and anthropometrics 
Body weight was not different between PL and CR before training or after eight 
weeks of a progressive resistance training program combined with two days of 
cardiovascular exercise. When data from PL and CR are combined, body mass did not 
change significantly due training (Figure 6). 
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PRE vs. POST 
PRE POST PRE POST 
PL CR 
Body mass before and after an 8-week moderate cardiovascular 
program combined with a progressive resistance training program and 
200 µg/day chromium picolinate (CR, n=6) and placebo (PL, n=6) 
supplementation. Data are means ± SE. Body mass did not change in 
CR or PL. 
Body Mass Index (weight (kg)/height (m2) was not different between PL and CR 
before training. However, following eight weeks ofresistance training and cardiovascular 
exercise, BMI of CR increased significantly with training (p = 0.02) while BMI in PL 
decreased steadily with each increase in training intensity, perhaps reflecting the changes in 
body weight in each group. 
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The sum of seven skinfolds did not change due to training or supplementation. 
However, the interaction of training intensity with supplementation was significant (p < 
0.02). The sum of seven skinfolds (Figure 7) decreased in PL (Pre= 128 mm± 11 vs. Post= 
121 mm± 11) and increased in CR (Pre 122 mm± 11 vs. Post 128 mm± 11). 
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Sum of7 skinfolds before and after an 8-week moderate cardiovascular 
program combined with a progressive resistance training program and 200 
µg/day chromim11 picolinate (CR, n=6) and placebo (PL, n=6) 
supplementation. Data are means ± SE. Sum of skinfolds increased 
significantly after training in CR (significant main effect; p < 0.02) and 
decreased in PL. 
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The sum of eight girths did not change significantly due to group nor to the 
interaction of group with training. When data from PL and CR are combined, the sum of 
eight girths (Figure 8) decreased significantly due to training (p < .003) (Pre= 509.3 mm± 
5.6 vs. Post= 500 mm± 5.6) involving both cardiovascular and resistance training exercise. 
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Sum of 8 girths before and after an 8-week moderate cardiovascular program 
combined with a progressive resistance training program and 200 µg/day 
chromium picolinate (CR, n=6) and placebo (PL, n=6) supplementation. Data 
are means ± SE. The sum of girths decreased significantly due to training 
alone (significant main effect; p < .003) in CR and PL. 
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CHAPTERV: 
DISCUSSION 
The purpose of this study was to examine the effects of chromium picolinate 
supplementation on changes in body weight and body composition when consumed in 
conjunction with a 'regular exercise program'. Chromium and chromium picolinate are 
marketed as weight loss enhancing supplements that increase lean body mass while 
decreasing body weight when taken in conjunction with a 'regular exercise program'. 
Although no specific exercise instructions are provided on product labels, the American 
College of Sports Medicine suggests that exercise intensities ofat least 60% of a lRM should 
be sufficient to increase strength. Additionally, the most rapid strength gains are achieved 
when a muscle is exercised at 80-100% of maximum exertion. To continue improving 
muscle strength with resistance training, resistance must be progressively increased to 
continue overloading the muscle. Furthermore, the ACSM recommends exercising at 70-
85% of the heart rate achieved on symptom-limited treadmill test, for 20-60 minutes, 3-5 
days per week. Thus, female subjects participated in progressive lower body resistance 
training and cardiovascular exercise program for eight weeks. One group consumed 200 µg 
of chromium picolinate daily throughout the 8-week training period while the other group 
received a placebo containing ,sucrose. 
Both the cardiovascular and resistance training regimes had a training effect on both 
groups of subjects. However, the extent of the training was not related to chromium 
supplementation. The amount of weight lifted in a lRM test on the leg press, knee extension 
and leg curl machines increased significantly due to the training but was not greater in the 
chromium supplemented group. Consequently, one may conclude that a training effect 
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occurred on the leg press machine in both PL and CR but was not enhanced by 
supplementation. However, training was not enhanced by supplementation. As described, 
these fmdings are consistent with previous research. 
Chromium supplementation is thought to potentiate the action of insulin and thereby 
increase muscle mass by increasing amino acid uptake into cells to be incorporated into 
contractile proteins and elicit muscle cell hypertrophy. Thus, chromium would also be 
expected to enhance muscular strength. However, this was not the case in this investigation 
or in previous investigations. Hallmark et al., found that chromium supplementation taken in 
conjunction with a progressive, 12-week resistance training program did not enhance strength 
gains nor increases in lean body mass in males. Additionally, Hasten, et al. examined the 
effects of chromium picolinate on muscular strength, muscle girths, and skinfolds in both 
male and female subjects. Sum of girths increased and sum of skinfolds decreased in both 
groups. However, only the male subjects significantly increased strength. Furthermore, only 
female subjects increased body weight. It was concluded that chromium picolinate 
supplementation had a greater effect on females than on males but did not enhance training. 
In the present study, the cardiovascular training also appeared to have been sufficient 
enough to elicit a cardiovascular training effect as demonstrated by the increased peak 
oxygen consumption and total exercise time in a graded exercise test post training. Although 
neither peak oxygen consumption nor exercise time was significantly different between 
groups, both factors increased significantly from pre to post training. Consequently, 
cardiovascular training was not enhanced with chromium supplementation either. Previous 
studies have demonstrated increased chromium losses following intense bouts of endurance 
exercise (7, 13, 70) and increased muscle tissue chromium levels in rats (70), but no 
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association has been made between chromium status and endurance performance in previous 
studies or in this investigation. Furthermore, no studies have included cardiovascular 
exercise in their training regime and analysis of body composition. 
Although changes in body mass of PL and CR were not significant, it is interesting to 
note that not only did CR weigh less than PL pre training, CR subjects weighed more post 
training. However, chromium supplementation did not enhance weight loss or changes in 
body fat in this study. Furthermore, as previously noted, Hasten et al. observed increased 
bodyweight in only women subjects taldng chromium with no significant change in the sum 
of skinfolds or muscle girths. Although one may speculate that the increased body weight in 
this study indicates an increase in lean body mass, no significant change in body composition 
was observed in either group. 
In this investigation, body fat percentages decreased slightly in PL but not 
significantly. However, PL started with greater percent body fat than CR and ended with a 
lesser percent body fat than CR. Thus, the decreased weight in PL may be attributed to fat 
loss. Furthermore, CR started with lower percent body fat than PL yet ended with higher 
percent body fat than PL. The increased percent body fat of CR was statistically significant 
indicating that the weight gain was not due to increased lean tissue. Furthermore, when 
measuring changes in the specific muscles exercised, calf skinfold thickness was 
insignificant and unrelated to group, training, or the interaction of group with the training. 
Furthermore, the thigh skinfold thickness of CR was significantly greater post training 
reinforcing the suggestion that the increase in body mass was not due to an increase in lean 
body mass. In fact, thigh skinfold thickness of CR increased steadily with each increase in 
training intensity while thigh skinfold thickness remained relatively constant in PL. Although 
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no significant difference was found in thigh skinfold thickness due to neither group nor the 
interaction of group with training, the increased thigh skinfold thickness was observed in 
only CR. 
In addition to the lower body skinfold sites, all individual skinfold sites were also 
examined. Abdominal skinfold measurements did not change significantly due to group or 
the interaction of group with training. However, the abdominal skinfold measurements of PL 
decreased to a greater extent than did CR. A significant difference in the abdominal skinfold 
from pre to post was found due to the training alone, aside from group, indicating that 
training alone did affect the size of abdominal skinfold measurement. Understanding the 
pattern of weight loss and gain in women, one may speculate that the decreased abdominal 
skinfold may account for the slight decrease in body fat observed in the sum of 7 skinfolds in 
PL. The pattern of weight loss/gain in woinen is understood to be that women lose weight in 
the following pattern: epigastric, lower gastric, gluteal, and femoral regions. Furthermore, it 
is the opposite pattern in regard to weight gain. Thus, although one would suspect that any 
changes in body composition would be reflected in the trained muscle groups, it may be that 
changes in the abdominal area also contributed even though no abdominal exercises were 
performed. 
In addition to expecting lower body skinfold measurements to decrease due to 
training, lower body girths were expected to increase. Chromium is thought to increase 
muscle mass by increasing amino acid uptake into cells for incorporation into contractile 
protein and stimulate muscle cell hypertrophy. However, the sum of 8 girths did not change 
significantly due to group nor to the interaction of group with training. However, the sum of 
8 girths decreased significantly due to training alone. Because the majority of girths taken 
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were from non-exercising muscles in the upper body, this finding demonstrates perhaps more 
the absence of upper body training rather than the presence oflower body training. In 
consideration of the two lower body girth measurements, no significant difference was found 
in the sum of the thigh and calf girths due to group, training, nor due to the interaction of 
group with training. Individual thigh and calf girths also did not change due to training, 
group, or the interaction of group with training. It is interesting that the sum of eight girths 
and the thigh and calf girth sums increased progressively through each training intensity up 
to the most intense training phase at which point girths decreased to the initial circumference. 
Although subjects were asked to continue training over spring break, exercise and food 
intake was not monitored for 10 days between training at 85% and 95% of the initial lRM's. 
Additionally, perhaps motivation levels decreased at such a high intensity. Furthermore, 
because a training effect was observed during the first two training stages, the fmal training 
intensity perhaps should have been based on the most recent 1 RM rather than the initial 
lRM. Although the exercises in this study targeted the femoral and gluteal regions, any 
change in physique may not manifest itself in these areas with such a short exercise program 
in women because of the pattern in which they tend to lose or gain weight. Thus, one may 
speculate that any measurable change in the lower body of female subjects would have to be 
accompanied by significant weight loss or a longer training period. 
In conclusion, the findings of this investigation agree with that of Hallmark et al. and 
Clancy et al. in that chromium did not facilitate changes in strength during a moderate 
exercise program including progressive lower body resistance training in female subjects. 
Chromium is thought to increase muscle mass by increasing amino acid uptake into cells for 
incorporation into contractile protein and stimulate muscle cell hypertrophy. Thus, the 
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increase in lean tissue would be expected to increase muscle strength, increase muscle 
hypertrophy, decrease body fat, and decrease body weight. Additionally, one would expect a 
significant increase in thigh girth with an accompanying decrease in thigh skinfold due to the 
training alone. However, this was not the case in this study. Although these results 
demonstrate the efficacy of the training program, thigh and calf girths did not increase, body 
fat did not decrease, and body weight did not decrease. It is suspected that the lack of 
measured change be due to the length of the training program, the small number of subjects, 
and lack of adequate stimulus in the later stages of training. 
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APPENDIX A: TRAINING REGIMEN 
Resistance Training Cardiovascular Training 
Week Intensity Sets/Repetitions Frequency Time Frequency 
I, II 65% lRM 3 x 12 repetitions MWF 30 min. T,Th 
III-VI 85% lRM 3 x 8-10 repetitions MWF 30 min. T,Th 
VII, VIII 95% lRM 5 x 3-5 repetitions MF 30 min. T,Th 
Exercise session procedure: 
Warm up 5 minutes performing light rhythmic, continuous movement 
Perform the demonstrated stretches for the quadriceps, hamstrings, and gastrocnemius. Hold 
each position 10-30 seconds. 
Resistance training: 
Perform each repetition slowly allowing 4-7 seconds for the entire movement pattern, 
i.e. 2-3 seconds through the concentric phase, 3-4 seconds in the eccentric phase. 
Rest 1-2 minutes between each set. Record all repetitions 
Cardiovascular training: 
Perform 30 minutes of continuous cardiovascular exercise on either the treadmill or 
cycle ergometer at an intensity high enough to elicit a heart rate equal to 65-70% of 
your V02peakHR as indicated on the Exercise Record. Fifteen-second heart rates will 
be taken manually during the 15th minute of the exercise session and during the last 
minute of the exercise session. 
Cool down for 5 minutes performing light, rhythmic, and continuous movement 
Repeat static stretches 
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APPENDIX B: SAMPLE EXERCISE RECORD 
Weeks I and II 
Workouts 1-6 
Name --------
Time _____ _ 
V02peak __ IIRmax __ _ 
70% V02peak __ _ HR.goal __ 
Cardiov~scular Exercise Duration 
Walking 
Running 
Stationary Cycling 
Resistance Training 
Exercise 
Initial lRM: 
Leg/Seat Adjustment: 
Intensity: 65% lRM= 
Goal #Reps: 8-12 
Leg Press 
Leg Curl 
Knee Extension 
Leg Press 
Set I 
5 minute cool down & stretching 
15 minute HR 
Leg Curl 
Set II 
Date _____ _ 
Workout# ___ _ 
30minuteHR 
Knee Ext. 
Set III 
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APPENDIX C: ANTHROPOMETRIC PROCEDURES 
ACSM's Guidelines/or Exercise Testing and Prescription. 1995. 
Skinfold measurements 
A fold of skin and subcutaneous fat is grasped with thumb and forefinger. The skin is pulled 
away from the underlying muscle, following the natural contours of the skin. The calipers 
are placed 1 cm away from the fingers, perpendicular to the skinfold and halfway between 
the base and crest of the skinfold. The measurement is read within two seconds (not longer) 
after the full force of the calipers has been applied. Pinch is maintained while reading 
caliper. The average of three measurements is recorded. If the three measurements are not 
within 1 to 2 millimeters of each other, retest. All measurements are taken on the right side 
of the body. 
Abdominal vertical fold 2 cm to the right of the umbilicus 
Triceps vertical fold on posterior midline of the upper arm, midway between acromion 
and olecranon processes 
Biceps 
Chest 
vertical fold on anterior aspect of arm, over belly of muscle, 1 cm above level 
of triceps site 
diagonal fold halfway between anterior axillary line and nipple (men) or one-
third the distance between anterior axillary line and nipple (women) 
Medial calf vertical fold at maximum circumference on midline of medial border 
Midaxillary vertical fold on midaxillary line at level ofxiphoid process 
Subscapular diagonal fold ( 45 degree angle) 1 to 2 cm below inferior angle of scapula 
Suprailiac diagonal fold in line with natural angle of iliac crest taken in the anterior 
axillary line immediately superior to the iliac crest 
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Thigh vertical fold on the anterior midline of the thigh midway between proximal 
border of patella and inquinal crease ( at hip) 
Circumference (girth) measurements 
All limb measurements are taken on the right side of the body using a tension-regulated tape. 
Subjects stand relaxed. Tape is placed perpendicular to the long axis of body part. Tape is 
pulled to the proper tension without pinching the skin. Duplicate measurements are taken. 
Retest if measures are not within 7 mm (.25 inches). 
Waist 
Abdomen 
Thigh 
Arm 
Forearm 
Wrist 
Hip 
Calf 
at narrowest part of torso (above umbilicus; below the xiphoid process) 
at the level of the umbilicus 
legs slightly apart, at maximal circumference of the thigh (below the gluteal 
fold) 
arms at side, midway between the acromion and olecranon processes 
arms slightly away from trunk, at the maximal forearm circumference 
over ulnar styloid 
at maximal circumference around buttocks or hips (whichever is greater) 
at maximum calf circumference 
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APPENDIX D: BODY COMPOSITION CALCULATIONS 
Seven-site formula 
Sites measured: chest, midaxillary, triceps, subscapular, abdomen, suprailiac, thigh 
Calculating Body Density for women: 
Body Density= 1.0970- 0.00046971(:r7 skinfolds) + 0.00000056(:r72)-
0.00012828(age) 
Three-site formula 
Sites measured: triceps, suprailiac, thigh 
Calculating Body Density for women: 
Body Density= 1.0994921 - 0.0009929(:r3) +0.0000023(:r32)-0.0001392(age) 
Calculating percent body fat 
Seven-site formula 
Percent Body Fat = 457 /Body Density - 414.2 
Three-site formula 
Percent Body Fat = 457 /Body Density - 414.2 
or 495/Body Density - 450 
or 495/Body Density - 450 
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APPENDIX E: SUBJECT SKINFOLD MEASUREMENTS 
Group I: Placebo (PL) 
Skinfold 
Site Pre Post 65% Post 85% Post 95% SEM 
Thigh 26.7 26.9 26.7 26.9 ±2.31 
Calf 17.1 17.0 16.3 17.3 ±2.57 
Abdominal 23.2 20.9 21.5 20.0 ±2.83 
Suprailiac 19.3 19.1 19.3 18.4 ±2.22 
Subscapular 17.9 18.1 19.0 17.3 ±2.69 
Midaxillary 13.3 14.3 12.5 12.0 ±1.75 
Chest 11.3 11.8 11.8 10.8 ±1.42 
Bicep 9.0 8.7 8.6 8.3 ±1.01 
Triceps 16.5 16.0 16.6 15.4 ±1.36 
"f.7 128.2 127.0 127.5 120.7 ±10.6 
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APPENDIX E CONTINUED: SUBJECT SKINFOLD MEASUREMENTS 
Group II: Chromium (CR) 
Skinfold 
Site Pre Post 65% Post 85% Post 95% SEM 
Thigh 26.5 27.2 29.6 30.7 ±2.31 
Calf 21.6 20.2 20.3 20.6 ±2.57 
Abdominal 24.4 21.7 24.0 22.6 ±2.83 
Suprailiac 17.5 18.2 18.4 19.7 ±2.22 
Subscapular 16.3 15.7 17.5 17.1 ±2.69 
Midaxillary 12.6 12.7 13.1 12.8 ±1.75 
Chest 8.0 8.2 9.5 9.0 ±1.42 
Bicep 8.7 8.0 8.5 7.7 ±1.01 
Tricep 16.6 16.5 17.4 16.5 ±1.36 
"f,7 121.9 120.2 129.5 128.3 ±10.6 
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APPENDIX F: SUBJECT GIRTH MEASUREMENTS 
Group I: Placebo (PL) 
Girth 
Site Pre Post 65% Post 85% Post 95% SEM 
Thigh 58.6 59.5 60.0 58.8 ±1.16 
Calf 36.7 36.8 37.3 36.7 ±0.85 
Hip 97.7 98.4 100.3 98.2 ±1.86 
Waist 72.5 73.4 73.3 72.0 ±1.25 
Abdomen 79.1 79.8 78.7 75.1 ±2.19 
Shoulder 103.3 103.6 103.6 101.7 ±1.45 
Upper Arm 27.0 26.9 26.8 26.3 ±0.64 
Neck 32.3 32.3 32.2 31.9 ±0.59 
L8 507.1 510.7 512.2 500.7 ±7.84 
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APPENDIX F CONTINUED: SUBJECT GIRTH MEASUREMENTS 
Group II: Chromium (CR) 
Skinfold 
Site Pre Post 65% Post 85% Post 95% SEM 
Thigh 59.6 60.4 60.1 60.1 ±1.16 
Calf 37.2 37.1 37.1 36.7 ±0.95 
Hip 99.5 101.7 100.6 99.4 ±1.86 
Waist 73.0 73.0 73.4 72.1 ±1.25 
Abdomen 78.9 80.1 79.4 75.8 ±2.19 
Shoulder 103.3 10.30 102.5 101.7 ±1.45 
Upper Arm 27.3 26.9 27.0 26.6 ±0.64 
Neck 32.6 32.3 32.2 32.0 ±0.59 
~8 511.5 514.6 512.4 499.1 ±7.84 
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